The Disruptors and Dominators newsletter, one of the “entry level” letters from Weiss, is out pitching a “silver bullet” company — a firm that has developed a universal cancer vaccine. And, of course, they’ll tell you all about it — for your $49 subscription fee. Here at Stock Gumshoe, we’d like you to think things […]
Articles
Immunotherapy for cancer has been in the news quite a bit in recent years, with several drugs making an impact on the worst cancers and giving some real hope for future advancement — not a small thing for a basic medical strategy that’s been tested and tweaked for 125 years now by folks following in […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Resverlogix has no ongoing clinical trial on the ClinicalTrials.gov site. Not sure what they are addressing. There are s...
For those considering Advaxis (ADXS) which Dr.KSS and Jean-Pierre Ruiz discussed earlier I found some non-scientific inf...
I appreciate JP Ruiz mining so much helpful information on Advaxis $ADXS. This company is a play on the immune stimul...
Advaxis (ADXS) is listed on the NASDAQ. It's 52-week range is $2.46 - $5.99 with average volume of 250,914 shares. Marke...